Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00022308

Public ClinicalTrials.gov record NCT00022308. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Trial of Radical Thoracic Radiation, Weekly CPT-11 (Irinotecan) and Cisplatin in Locally Advanced Non-Small Cell Lung Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have locally advanced non-small cell lung cancer.

Study identification

NCT ID: NCT00022308
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Fox Chase Cancer Center; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Lung Cancer

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 1998
Primary completion: Aug 31, 2006
Completion: Aug 31, 2006
Last update posted: Sep 1, 2013

1999 – 2006

United States locations

U.S. sites: 8
U.S. states: 2
U.S. cities: 8

Facility	City	State	ZIP	Site status
South Jersey Regional Cancer Center	Millville	New Jersey	08332	—
Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County	Mount Holly	New Jersey	08060	—
Riverview Medical Center - Booker Cancer Center	Red Bank	New Jersey	07701	—
Community Medical Center	Toms River	New Jersey	08755	—
St. Francis Medical Center	Trenton	New Jersey	08629	—
Delaware County Memorial Hospital	Drexel Hill	Pennsylvania	19026	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
Reading Hospital and Medical Center	Reading	Pennsylvania	19612-6052	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00022308, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2013 · Synced Sep 15, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00022308 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →